证券代码：600222 证券简称：太龙药业 编号：临 2021-029 河南太龙药业股份有限公司 关于参加河南辖区上市公司 2021 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强投资者的互动交流，河南太龙药业股份有限公司定 于 2021 年 6 月 8 号（周二）16:00-17:20 参加在全景网举办的"真 诚沟通 传递价值"河南辖区上市公司 2021 年投资者网上集体接待日 活动，本次活动将采用网络远程的方式举行，投资者可登录"全景·路 演天下"（http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司董事兼总经理罗剑 超先生、董事会秘书冯海燕女士（如有特殊情况，参会人员将可能进 行调整），欢迎广大投资者积极参与。 特此公告。 河南太龙药业股份有限公司董事会 2021 年 6 月 4 日 ...

2021 年第一季度报告 公司代码：600222 公司简称：太龙药业 河南太龙药业股份有限公司 2021 年第一季度报告 1 / 25 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 9 | 2021 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人李景亮、主管会计工作负责人赵海林及会计机构负责人（会计主管人员）胡志权 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | | | | 单位：元币种：人民币 | | | --- | --- | --- | --- | --- | | | 本报告期末 | 上年度末 | 本报告期末比上年度末 | | | | | | 增减(%) | | | 总资产 | 3,739,251,867.46 | 3 ...

Financial Performance - In 2020, the company achieved a net profit attributable to shareholders of 29,240,862.39 CNY, a decrease of 34.16% compared to the previous year[5]. - The total operating revenue for 2020 was 1,417,097,311.59 CNY, representing an increase of 8.03% from 2019[25]. - The company reported a significant decline in net profit compared to 2019, which was 44,414,622.07 CNY[25]. - The company's net profit attributable to shareholders decreased by 34.16% year-on-year, primarily due to increased raw material costs and fixed expenses during the pandemic[28]. - Basic earnings per share decreased by 33.04% to RMB 0.0535, reflecting the overall decline in profitability[27]. - The weighted average return on equity fell to 2.10%, a decrease of 1.08 percentage points compared to the previous year[27]. - The company reported a total revenue of 15,278,169.32, with a year-on-year increase of 5,772,488.18[35]. - The company achieved operating revenue of 1,417.10 million yuan in 2020, representing a year-on-year growth of 8.03%[62]. - The net profit attributable to shareholders was 29,240,900 CNY, with a net profit of 13,962,700 CNY after deducting non-recurring gains and losses[62]. Cash Flow and Dividends - The cash dividend proposed is 0.16 CNY per share, totaling 9,008,642.82 CNY, which accounts for 30.81% of the net profit attributable to shareholders[5]. - As of December 31, 2020, the profit available for distribution to shareholders was 184,253,477.46 CNY[5]. - Operating cash flow increased by 76.82% year-on-year, attributed to a higher proportion of cash collections during the reporting period[29]. - The company reported a significant increase in net cash flow from operating activities, amounting to 73,427,546.30 CNY, a 76.82% increase compared to the previous year[64]. - Net cash inflow from financing activities was 209.57 million yuan, a significant increase of 211.48% year-on-year, driven by increased bank financing and capital contributions[83]. Investments and Acquisitions - The company acquired a 33.95% stake in Tailong Health, increasing its ownership to 80.40%, allowing for control over the entity[27]. - The company increased its investment in the healthcare sector, acquiring control of Tailong Health Industry Investment Co., Ltd., and established two funds with a fair value increase of 24.6 million CNY during the reporting period[60]. - The company completed a capital increase of RMB 130 million from Jinggang Fund, acquiring a 20% stake in Shenlanhai[157]. - The company acquired 33.95% equity of Tailong Health from its controlling shareholder for RMB 127.9 million during the reporting period[157]. Revenue by Segment - Revenue from traditional Chinese medicine oral liquid products increased by 35.88% year-on-year, driven by market demand during the pandemic[28]. - The pharmaceutical formulation business generated revenue of 478.93 million yuan, with a year-on-year increase of 32.76%[56]. - The revenue from the clinical CRO services segment was 238.79 million yuan, reflecting a year-on-year growth of 6.45%[59]. - Revenue from traditional Chinese medicine pieces decreased by 4.00% year-on-year, with a gross margin decline of 18.69 percentage points[70]. - Pharmaceutical distribution revenue fell by 31.29% year-on-year, primarily due to the company's strategic adjustment to reduce drug distribution operations[70]. - Revenue from herbal medicine trading increased by 31.50% year-on-year, driven by growth in orders for high-quality ecological medicinal materials[70]. Research and Development - The company aims to enhance its drug research and development services, focusing on reducing risks and shortening development cycles for clients[37]. - The company’s R&D services cover the entire pharmaceutical development chain, including preclinical research and clinical CRO services, aimed at maximizing client returns by reducing time and cost[41]. - R&D expenses rose by 7.21% to 63,664,588.06 CNY, reflecting the company's commitment to innovation[64]. - The company has over 80 ongoing R&D projects, primarily in cardiovascular, anti-tumor, and digestive system areas, including clinical trials for new drugs[107]. - R&D investment for the reporting period accounted for 4.50% of total revenue, with a year-on-year increase of 7.13% in R&D spending[112]. Corporate Governance and Compliance - The company has committed to reducing and regulating related party transactions with its controlling shareholders to avoid conflicts of interest[144]. - The controlling shareholder promised not to engage in any competitive business activities within China that could harm the company's interests[144]. - The company is focused on ensuring compliance with legal and regulatory requirements in all related party transactions[144]. - The company aims to maintain transparency and fairness in its dealings with related parties to protect shareholder interests[144]. - The company has implemented the new revenue recognition standards since January 1, 2020, which did not have a significant impact on its financial position and operating results[147]. Environmental Responsibility - The company reported that the concentrations and total emissions of SO2 and nitrogen oxides from both production sites were below the approved discharge limits[179]. - The company has not experienced any environmental pollution incidents or received administrative penalties during the reporting period[173]. - The wastewater treatment facility has a daily processing capacity of 1,000 tons, and the treatment process includes multiple stages to ensure compliance with discharge standards[177]. - The company has implemented a self-monitoring scheme for environmental compliance, with third-party monitoring showing all pollutants meet discharge standards[182]. Shareholder Information - The total number of ordinary shares after the recent changes is 573,886,283, with 99.39% being freely tradable[187]. - The company completed a non-public issuance of A-shares totaling 77,277,371 shares, increasing the total share capital from 496,608,912 shares to 573,886,283 shares[188]. - The total number of ordinary shareholders increased from 45,174 to 50,196, representing a growth of approximately 11.3%[191]. - The largest shareholder, Zhengzhou Zhongsheng Industrial Group Co., Ltd., holds 132,441,168 shares, accounting for 23.08% of the total shares[194]. Social Responsibility - The company donated 6 million RMB worth of medicines to medical and public welfare institutions in response to the COVID-19 pandemic[171]. - The company has established long-term stable Chinese medicinal material supply bases to support local farmers, contributing to poverty alleviation efforts[167]. - The company reported a total of 37.14 million RMB invested in poverty alleviation initiatives during the reporting period[168].

Financial Performance - Operating income for the first nine months reached CNY 965,229,694.68, an increase of 8.64% year-on-year[7] - Net profit attributable to shareholders decreased by 10.37% to CNY 29,499,856.77 compared to the same period last year[7] - The company reported a basic earnings per share of CNY 0.0540, down 8.63% from the previous year[7] - The net profit after deducting non-recurring gains and losses increased by 35.61% to CNY 20,621,385.28 compared to the same period last year[7] - Net profit for Q3 2020 was ¥1,330,000.02, a decrease of 79.5% from ¥6,493,222.06 in Q3 2019[35] - The net profit for Q3 2020 was a loss of ¥22,547,648.36, compared to a profit of ¥14,178,989.20 in Q3 2019, indicating a significant decline in profitability[40] - The total comprehensive income attributable to the parent company for Q3 2020 was ¥83,341,360.18, compared to ¥6,698,948.42 in Q3 2019, showing a substantial increase[41] Assets and Liabilities - Total assets increased by 10.39% to CNY 3,023,968,298.29 compared to the end of the previous year[7] - Total current assets increased to ¥1,866,118,599.21 as of September 30, 2020, up from ¥1,726,827,217.33 on December 31, 2019, representing an increase of approximately 8.06%[25] - Total liabilities increased to ¥1,600,877,735.09 from ¥1,427,620,873.26, indicating a rise of approximately 12.09%[27] - The company reported a total equity of ¥1,423,090,563.20, up from ¥1,311,802,430.56, representing an increase of approximately 8.49%[27] - The company’s total liabilities to total assets ratio stands at approximately 52.93% as of September 30, 2020, compared to 52.1% at the end of 2019[27] - Total liabilities reached ¥1,427,620,873.26, with current liabilities at ¥892,470,394.21 and non-current liabilities at ¥535,150,479.05[51] Cash Flow - Net cash flow from operating activities improved significantly, reaching CNY 21,383,911.63, a 126.10% increase from the previous year[7] - The company reported a net cash flow from operating activities of RMB 21,383,911.63, a 126.10% increase compared to the previous period, driven by higher sales receipts[19] - The net cash flow from operating activities for Q3 2020 was ¥21,383,911.63, a significant improvement from a net outflow of ¥81,922,985.67 in Q3 2019[44] - Total cash inflow from investment activities was ¥1,108,000,671.76, compared to ¥394,745,756.78 in the same period last year, indicating a substantial increase[44] - The net cash flow from investment activities was -¥73,243,860.13, a decline from a positive net cash flow of ¥68,775,638.45 in Q3 2019[44] - Cash inflow from financing activities totaled ¥849,230,684.56, up from ¥537,730,162.91 in Q3 2019[45] - The net cash flow from financing activities was ¥122,131,564.04, a recovery from a net outflow of -¥263,505,071.73 in Q3 2019[45] Shareholder Information - The number of shareholders at the end of the reporting period was 52,919[12] - The largest shareholder, Zhengzhou Zhongsheng Industrial Group, holds 23.08% of the shares, with 132,441,168 shares pledged[12] Investments and Subsidiaries - Long-term equity investments increased by 111.07% to RMB 184,515,851.84, primarily due to investments in Tai Long Health and Tai Long Network Technology[15] - The company signed an investment agreement with Jinggang Fund for RMB 13 million to acquire a 20% stake in Zhengzhou Deep Blue Sea Biotechnology, which will impact its ownership in Beijing New Leading Pharmaceutical Technology[19] - The company reported a significant decrease in investment income, with a loss of RMB 897,620.49 compared to a profit of RMB 6,121,132.86 in the previous year, primarily due to the disposal of subsidiary equity[18] - The company received government subsidies totaling RMB 17,816,076.38, marking a 68.39% increase compared to the previous year[18] Research and Development - Research and development expenses for Q3 2020 amounted to ¥19,532,536.67, representing a 32% increase from ¥14,788,841.99 in Q3 2019[34] - The company plans to continue focusing on R&D to enhance product offerings and market competitiveness despite the current financial challenges[40]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥647,757,181.42, representing a 9.21% increase compared to ¥593,122,061.88 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was ¥28,178,558.53, up 7.49% from ¥26,215,700.52 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was ¥24,585,801.90, which is an increase of 78.86% compared to ¥13,746,194.92 in the same period last year[18]. - The net cash flow from operating activities was ¥19,182,706.28, a significant improvement from a negative cash flow of -¥52,211,949.12 in the previous year, marking a 136.74% increase[19]. - Basic earnings per share for the first half of 2020 were ¥0.0516, a 10.26% increase from ¥0.0468 in the same period last year[20]. - The company's total revenue for the reporting period was 647.76 million yuan, an increase of 9.21% compared to the previous year[46]. - The company's gross profit margin decreased due to rising raw material costs, despite increased sales from key products[40]. - The company reported a net profit of CNY 185.13 million, a 34.68% increase compared to CNY 137.46 million in the previous period[58]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,784,213,209.15, reflecting a 1.64% increase from ¥2,739,423,303.82 at the end of the previous year[19]. - The total liabilities were RMB 1,444,472,707.91, compared to RMB 1,427,620,873.26, showing an increase of approximately 1.18%[124]. - The company's short-term borrowings increased to RMB 615,884,326.87 from RMB 574,900,000.00, reflecting a rise of about 7.00%[123]. - The company's total liabilities as of June 30, 2020, were ¥1,027,742,604.00, slightly up from ¥1,026,485,663.16 at the end of 2019[128]. Research and Development - The company’s R&D services aim to reduce risks and shorten development cycles for pharmaceutical companies[28]. - The company’s R&D services include clinical research, registration applications, and technology transfer[28]. - Research and development expenses increased by 16.97% to 26.29 million yuan, reflecting the company's commitment to enhancing R&D capabilities[46]. - The company is recognized as a key high-tech enterprise and has a research team of over 500 experts, enhancing its R&D capabilities[37]. Market and Product Development - The company's main product, Shuanghuanglian Oral Liquid, saw significant sales growth in the first quarter due to the pandemic, contributing to overall revenue and profit growth[20]. - The pharmaceutical formulation business achieved revenue of 274.75 million yuan, a year-on-year increase of 66.62%[40]. - The company continues to expand its marketing network and invest in drug research and development to enhance its core competitiveness[39]. - The company focuses on traditional Chinese medicine development, leveraging national policies to strengthen its market position and product differentiation[31]. Environmental and Social Responsibility - The company has not experienced any environmental pollution incidents or received administrative penalties during the reporting period[91]. - The company is enhancing its environmental risk management by investing in new technologies and equipment to comply with stricter environmental regulations[64]. - The company engaged in precision poverty alleviation by establishing stable Chinese medicinal material supply bases and employing local farmers, contributing to local employment[84]. - The company donated a total of 1.2 million yuan worth of medicines to hospitals in Wuhan and 4.42 million yuan to charity organizations during the COVID-19 pandemic[104]. Shareholder and Equity Information - The total number of shares increased from 496,608,912 to 573,886,283 due to a non-public issuance of 77,277,371 shares[109]. - The largest shareholder, Zhengzhou Zhongsheng Industrial Group Co., Ltd., holds 132,441,168 shares, representing 23.08% of the total shares[115]. - The company has a total of 573,886,283 shares outstanding, with 570,382,633 being unrestricted[108]. - The company did not propose any profit distribution or capital reserve transfer for the first half of 2020, indicating a focus on reinvestment[68]. Financial Reporting and Compliance - The company has implemented a new revenue recognition policy effective from January 1, 2020, which is not expected to significantly impact its net profit or total assets[103]. - The financial statements are prepared based on the going concern principle and comply with the relevant accounting standards[163]. - The company confirms that its financial statements reflect a true and complete view of its financial position and performance[166]. - The company has no significant doubts regarding its ability to continue as a going concern for the next 12 months[164].

2020 年第一季度报告 公司代码：600222 公司简称：太龙药业 河南太龙药业股份有限公司 2020 年第一季度报告 1 / 25 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 9 | 2020 年第一季度报告 一、 重要提示 1.4 本公司第一季度报告未经审计。 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人李景亮、主管会计工作负责人赵海林及会计机构负责人（会计主管人员）胡志权 保证季度报告中财务报表的真实、准确、完整。 2020 年第一季度报告 | 项目 | 本期金额 | 说明 | | --- | --- | --- | | 计入当期损益的政府补助，但与公司 | | 主要是本期收到与日常经营相关 | | 正常经营业务密切相关，符合国家政 | 6,271,404.55 | | | 策规定、按照一定标准定额或定量持 | | 的政府 ...

Financial Performance - The company's operating revenue for 2019 was CNY 1,311,814,818, representing a year-on-year increase of 9.79%[21] - The net profit attributable to shareholders for 2019 was CNY 45,711,888, a significant recovery from a loss of CNY 115,318,228 in 2018[21] - The basic earnings per share for 2019 was CNY 0.0822, compared to a loss of CNY 0.2009 per share in 2018[23] - The weighted average return on equity increased to 3.43% in 2019, up by 11.48 percentage points from -8.05% in 2018[23] - Revenue from pharmaceutical formulation business grew by 49.11% year-on-year, while revenue from traditional Chinese medicine slices increased by 12.08%[23] - The net profit attributable to shareholders increased significantly compared to 2018, driven by growth in the pharmaceutical formulation business and an increase in government subsidies, along with the divestiture of loss-making assets[24] - The company achieved operating revenue of 1,311.81 million yuan, a year-on-year increase of 9.79%[49] - The net profit attributable to shareholders was 45.71 million yuan, marking a significant turnaround from losses[49] Cash Flow and Assets - The net cash flow from operating activities decreased by 63.42% to CNY 43,700,589 in 2019[21] - Total assets at the end of 2019 were CNY 2,739,423,303.8, down 3.38% from the previous year[21] - The net cash flow from operating activities showed significant fluctuation, with a net cash outflow of ¥1,951.03 million in Q1 and a net inflow of ¥12,562.36 million in Q4[26] - The company’s cash flow from operating activities was impacted by seasonal sales fluctuations and strategic procurement measures for raw materials[27] - The company reported a significant decline in revenue from pharmaceutical distribution, down 68.99%, due to strategic adjustments and the transfer of two subsidiaries[60] - The net cash flow from financing activities saw a drastic decline of 474.68%, amounting to -¥240,886,583.18[55] - The company's cash and cash equivalents decreased by 40.59% to ¥398,091,340.10, primarily due to share repurchases and repayment of due borrowings[79] Business Operations and Strategy - The company operates in the pharmaceutical manufacturing industry, focusing on four main business segments: drug formulation, traditional Chinese medicine (TCM) decoction pieces, drug research and development services, and drug material circulation[34] - The company is expanding its market presence by deepening channel development and enhancing brand influence through its TCM cultural heritage[39] - The company is focusing on expanding its market presence in regions such as North China and East China, where sales of Chinese herbal oral liquids have significantly increased[60] - The company is actively pursuing international standardization for its products, with support from 14 ISO member countries for its collaboration with Tsinghua University[50] - The company is committed to exploring differentiated development paths for traditional Chinese medicine, combining classic and modern innovations[88] Research and Development - The company’s drug research services are designed to help pharmaceutical companies reduce R&D risks and shorten development cycles, achieving industry-leading levels in key technologies[36] - The total R&D investment was CNY 59,557,237.49, representing 4.54% of total revenue[72] - The company has a total of over 50 R&D projects in reserve, focusing on cardiovascular, anti-tumor, and digestive system areas, as well as clinical trial technology research for new drugs[96] - The company’s R&D investment for the classic prescription series reached 17,265,464.75 RMB, with a significant increase of 313.85% compared to the previous year[98] - The company plans to continue its R&D strategy in 2020, focusing on standardized planting of traditional medicinal materials and the development of innovative drugs[104] Shareholder and Dividend Policy - The company plans not to distribute profits for 2019 and will not increase capital from reserves, focusing on share repurchase instead[5] - The company has a cash dividend policy that stipulates at least 10% of the distributable profit must be distributed in cash if conditions are met[135] - The company did not propose a cash dividend plan for 2019 due to the share repurchase and negative retained earnings[141] - The company’s profit distribution plan must be approved by more than half of the shareholders present at the meeting[136] Corporate Governance and Compliance - The company has established a commitment to avoid competition with Tai Long Pharmaceutical, ensuring that no direct or indirect participation in competing businesses occurs[144] - The company guarantees compliance with relevant regulations from the China Securities Regulatory Commission and the stock exchange regarding related party transactions[146] - The company has made commitments to notify of any competitive business opportunities that may arise[145] - The company emphasizes the importance of equal rights for all shareholders and the avoidance of transferring profits through related party transactions[146] Social Responsibility and Environmental Impact - The company actively engages in social responsibility initiatives, including employee welfare and community service, contributing to regional economic development[167] - The company’s environmental protection measures include upgrading pollution control facilities to ensure compliance with environmental standards[169] - The company invested RMB 37.14 million in poverty alleviation projects, specifically in agricultural development, with two projects initiated during the reporting period[165] - The company achieved a 100% compliance rate for wastewater and waste gas emissions, with a solid waste recovery rate of no less than 95%[171]

1.3 公司负责人李景亮、主管会计工作负责人赵海林及会计机构负责人（会计主管人员）胡志权 保证季度报告中财务报表的真实、准确、完整。 2019 年第三季度报告 公司代码：600222 公司简称：太龙药业 河南太龙药业股份有限公司 2019 年第三季度报告 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 10 | 2019 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.4 本公司第三季度报告未经审计。 | | 本报告期末 | 上年度末 | 本报告期末比上 年度末增减(%) | | | --- | --- | --- | --- | --- | | 总资产 | 2,618,953,358.16 | 2,835,342,435.60 | | -7.63 | | 归属于上市公司股东的净 | 1,30 ...

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 593,122,061.88, representing a 1.71% increase compared to CNY 583,145,473.34 in the same period last year[18]. - Net profit attributable to shareholders reached CNY 26,215,700.52, a significant increase of 848.78% from CNY 2,763,088.10 in the previous year[18]. - The basic earnings per share rose to CNY 0.0468, up 875.00% from CNY 0.0048 in the same period last year[19]. - The weighted average return on net assets increased to 1.93%, up 1.74 percentage points from 0.19% in the previous year[19]. - The company reported a net cash flow from operating activities of -CNY 52,211,949.12, a decline of 311.83% compared to -CNY 12,678,018.14 in the same period last year[18]. - Total assets decreased by 7.41% to CNY 2,625,178,885.13 from CNY 2,835,342,435.60 at the end of the previous year[18]. - The net assets attributable to shareholders decreased by 5.68% to CNY 1,309,761,942.25 from CNY 1,388,624,666.07 at the end of the previous year[18]. Business Strategy and Operations - The company has adjusted its revenue structure, significantly reducing its pharmaceutical distribution business while expanding its pharmaceutical formulation, traditional Chinese medicine, and drug research services[20]. - The company has successfully divested some loss-making assets, leading to a substantial increase in net profit compared to the previous year[20]. - The company is focused on expanding its main businesses, which has driven overall revenue growth despite the reduction in pharmaceutical distribution[20]. - The company operates in the pharmaceutical manufacturing industry, focusing on four main business segments: pharmaceutical preparations, traditional Chinese medicine pieces, drug research and development services, and drug material circulation[25]. - The pharmaceutical preparations segment includes over 100 products, with leading products like the Shuanghuanglian oral liquid series and Shuangjinlian mixture, achieving a leading market share in their categories[26]. - The company’s drug research and development services are primarily conducted by its subsidiary, focusing on areas such as cardiovascular, oncology, and pediatric medications, achieving industry-leading levels in key technologies[27]. - The company has a comprehensive procurement strategy to ensure high-quality raw materials, utilizing centralized purchasing for bulk materials and public bidding for packaging materials to reduce costs[28]. - The production process adheres strictly to GMP standards, ensuring quality control throughout the entire production cycle, from raw material procurement to final product testing[28]. - The sales model for pharmaceutical preparations primarily involves a distribution strategy through selected qualified distributors, enhancing market coverage across various healthcare institutions[28]. - The company’s traditional Chinese medicine pieces are distributed through its own commercial channels, providing added value services like herbal decoction to enhance competitiveness[28]. - The company is expanding its market presence through strategic partnerships with major pharmacy chains to increase brand influence and product availability[28]. Financial Gains and Losses - The company reported a non-recurring profit of 12,469,505.60, with significant contributions from government subsidies amounting to 7,010,000.00 and non-operating income of 4,942,245.87 from asset disposals[23]. - The total non-recurring gains include a tax impact of -1,351,490.15, indicating a net effect on the company's financial performance[23]. - Investment income surged by 257.35% to 7.06 million yuan, primarily due to the recognition of gains from the transfer of equity in He Luo Tai Long[50]. - The company reported a total of CNY 152,744,755.58 in restricted assets, primarily due to collateral for borrowings[56]. - The company’s net profit from its main subsidiary, Tong Jun Tang Pharmaceutical Co., Ltd., was CNY 930,370.00, contributing to overall profitability[63]. Market and Industry Context - The pharmaceutical manufacturing industry achieved a revenue of CNY 1,222.75 billion in the first half of 2019, with a cumulative growth of 8.5%[31]. - The total profit for the pharmaceutical manufacturing industry in the same period was CNY 160.82 billion, reflecting a cumulative growth of 9.4%[31]. - The production volume of traditional Chinese medicine (TCM) reached 1.481 million tons in the first half of 2019, with a cumulative growth of 10.9%[31]. - The company has been recognized as one of the "Top 100 Chinese Traditional Medicine Enterprises" for 2018 and awarded for its brand influence in 2019[32]. - The company has established a multi-platform layout in drug formulation, TCM decoction pieces, drug research and development, and drug material circulation[32]. - The company has a strong brand advantage, with its "Tailong" trademark recognized as a "Chinese Famous Trademark" and its products receiving various awards[35]. - The company has over 100 types of products, including proprietary and patented products, enhancing its market competitiveness[36]. - The company is a high-tech enterprise recognized by the state, with a focus on drug research and development, particularly in the field of chemical drug synthesis[38]. - The company has established a leading R&D team and has received multiple honors for its contributions to traditional Chinese medicine culture[39]. Risk Management - The company faces significant industry policy risks due to increasing regulatory measures in the pharmaceutical sector, which may impact future development[65]. - Market risks include intensified competition and regulatory changes leading to price reductions, affecting the company's operational and profit growth[66]. - R&D risks are highlighted by the high difficulty and long timelines associated with new drug development, which could adversely affect long-term growth if projects fail[66]. - The company has implemented strict accounts receivable management to mitigate risks associated with increased operational costs due to growing receivables[66]. - The company is committed to enhancing its R&D capabilities by collaborating with renowned research institutions and attracting high-level talent[66]. - The company aims to adapt its marketing strategies to align with market demands and improve its core competitiveness[65]. - The company will closely monitor national policy trends to adjust its operational strategies accordingly[65]. - The company emphasizes the importance of internal control and daily management of accounts receivable to ensure operational quality[66]. - The company is focused on developing new products and technologies to reduce R&D risks and enhance its product portfolio[66]. Shareholder and Equity Structure - The unlocking ratio for shares is set at 10% for the current period, with a total unlocking ratio of 60% over 60 months[72]. - Wu Lan and Tao Xinhua have committed to avoiding any competitive business activities with the listed company and its controlled enterprises during the shareholding period[72]. - Wu Lan and Tao Xinhua will reduce and regulate related party transactions with the listed company and its controlled enterprises[72]. - If Tao Xinhua violates the commitment of tenure, Wu Lan will pay 25% of the transaction consideration as compensation to Tai Long Pharmaceutical in cash[72]. - The commitment includes that Tao Xinhua will serve for no less than five full calendar years after the transfer of shares to Tai Long Pharmaceutical[72]. - The company will ensure that any necessary related party transactions are conducted at market prices and in compliance with legal regulations[72]. - Wu Lan and Tao Xinhua will not engage in any activities that harm the legal rights of the listed company and its shareholders[72]. - The company has established measures to avoid any potential competition with its controlling shareholder, Zhengzhou Zhongsheng Industrial Group[72]. - The commitment to avoid competition applies to any form of business activities within China[72]. - The company emphasizes the importance of compliance with legal obligations regarding related party transactions[72]. - The company committed to fair market principles in all transactions and will not engage in illegal activities that harm shareholder rights[73]. - The controlling shareholder provided a commitment to avoid competing businesses, ensuring no direct or indirect participation in activities that compete with the company's products[73]. - The company aims to reduce related party transactions with Tai Long Pharmaceutical and will ensure that unavoidable transactions are conducted on an equal and fair basis[73]. - The company expects to conduct daily related transactions with affiliated parties totaling no more than 43 million yuan in 2019, with actual transactions amounting to 20.9364 million yuan as of the report date[78]. Environmental and Social Responsibility - The company has invested a total of 18.57 million RMB in poverty alleviation projects during the reporting period[86]. - Two industry poverty alleviation projects have been initiated, focusing on traditional Chinese medicine cultivation and processing[84]. - The company has signed land transfer agreements with local farmers, ensuring compliance with contract terms[87]. - The company aims to maintain a 100% compliance rate for wastewater and waste gas emissions, with a solid waste recovery rate of no less than 95%[90]. - The company has successfully completed the re-certification of its pharmaceutical operating license, valid until April 1, 2024[94]. - The company’s production lines for traditional Chinese medicine have passed GMP re-certification, ensuring compliance with quality standards[94]. - The company plans to continue its poverty alleviation efforts in collaboration with local governments to achieve effective results[88]. - The company has upgraded its environmental protection facilities to ensure high standards of pollutant treatment and emissions[90]. Financial Reporting and Compliance - The company adheres to the accounting standards set by the Ministry of Finance and the China Securities Regulatory Commission for financial reporting[156]. - The company’s accounting period runs from January 1 to December 31 each year[160]. - The company’s accounting currency is Renminbi[162]. - The company has confirmed that there are no significant doubts regarding its ability to continue as a going concern for the next 12 months[157]. - The company recognizes goodwill when the purchase price exceeds the fair value of identifiable net assets acquired in a business combination[168]. - The fair value of identifiable assets and liabilities acquired must be measured at the acquisition date, with any excess of purchase price over fair value recognized as goodwill[169]. - The company will not recognize deferred tax assets related to deductible temporary differences if they do not meet recognition criteria at the acquisition date[169]. - Transaction costs related to the business combination, such as audit and legal services, are expensed as incurred[170]. - The company assesses whether multiple transactions should be treated as a single transaction based on specific criteria, including interdependence and economic rationale[173]. - The company consolidates financial statements based on control, reflecting the overall financial position and performance of the group[175]. - Unrealized internal transaction gains or losses from asset sales between subsidiaries are fully offset against net profit attributable to the parent company[176]. - The company does not adjust the opening balances of consolidated financial statements for subsidiaries acquired through business combinations[177]. - The company includes the income, expenses, and cash flows of newly acquired subsidiaries in the consolidated financial statements from the acquisition date[177]. - The company evaluates control over investees based on substantive rights and the ability to influence returns[174]. - The company acquired minority stakes in subsidiaries, adjusting capital reserves and retained earnings based on the difference between the fair value of the investment and the net asset share from the acquisition date[178]. - The company partially disposed of long-term equity investments without losing control, with the disposal price adjusted against the net asset share, impacting capital reserves and retained earnings[179]. - The company reported that any loss of control over subsidiaries would result in re-measurement of remaining equity at fair value, with the difference recognized as investment income in the period of loss[180]. - The company confirmed that joint arrangements are classified based on rights and obligations, distinguishing between joint operations and joint ventures[182]. - The company applies the spot exchange rate on the transaction date for foreign currency transactions, with monetary items re-measured at the balance sheet date[184]. - The company recognizes financial instruments upon entering into contracts, with conditions for derecognition of financial assets and liabilities clearly defined[187]. - Financial assets are classified at initial recognition based on the management's business model and cash flow characteristics, with specific categories for measurement[189]. - The company ensures that financial assets measured at amortized cost meet specific criteria related to cash flow payments[189]. - The company adjusts other comprehensive income for foreign currency translation differences upon disposal of foreign operations[185]. - The company’s consolidated statement of changes in equity is prepared based on the consolidated balance sheet and income statement[181]. - Financial assets measured at fair value and changes recognized in other comprehensive income include debt instruments that meet specific criteria, with interest income recognized using the effective interest method[190]. - The company classifies financial liabilities at initial recognition as either measured at fair value with changes recognized in profit or loss, or other financial liabilities, with transaction costs directly expensed for the former[192]. - Expected credit losses are recognized based on the difference between the contractual cash flows expected to be received and the cash flows expected to be collected, with specific methods for measuring losses on different types of financial assets[198]. - The company assesses whether credit risk has significantly increased since initial recognition, using various factors such as adverse changes in the debtor's financial condition[196]. - Financial guarantee contracts are initially measured at fair value and subsequently measured at the higher of the expected credit loss provision and the initial recognition amount less cumulative amortization[200]. - Financial assets and liabilities can be offset and presented at their net amount in the balance sheet if certain conditions are met, including having a legally enforceable right to offset[199]. - The company uses a simplified approach for measuring expected credit losses on lease receivables and accounts receivable, estimating losses over the entire lifetime of the asset[195]. - The company recognizes impairment losses on financial assets when there is evidence of a significant adverse effect on future cash flows due to specific events[196]. - Financial assets measured at fair value with changes recognized in profit or loss include trading financial assets and those designated at initial recognition, with all fair value changes recognized in profit or loss[191]. - The company applies the effective interest method for other financial liabilities, measuring them at amortized cost[193].

证券代码：600222 股票简称：太龙药业 编号：临 2019-043 河南太龙药业股份有限公司 关于参加 2019 年河南上市公司投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 ： ● 会议召开时间：2019 年 6 月 27 日14:30-17:30 ，16:00 开始网上 交流 ● 会议召开地点：投资者互动平台（http://rs.p5w.net） ● 会议方式 ：网络互动 一、活动主题 河南太龙药业股份有限公司（以下简称"公司"）2018年年度报 告已于2019年3月30日披露。为方便广大投资者更好、更全面地了解 公司的运营状况，进一步加强与投资者的沟通与联系，公司决定参加 由河南上市公司协会主办的"2019年河南上市公司投资者网上集体 接待日"活动，就 2018 年年报、公司治理、发展战略、经营状况、 融资计划、投资者保护、可持续发展等问题与投资者进行充分沟通。 二、召开的时间、方式 1、召开时间：2019年6月27日14:30-17:30，16:00 开始网上交 ...